These findings are consistent with imatinib’s multi-kinase inhibition profile, particularly against PDGFR, c-KIT, and ABL kinases, and suggest broad repositioning opportunities across CNS, cardiovascular, metabolic, and autoimmune conditions. The gene discussed is ABL1; the disease is Autoimmunity.